Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC):: The STELLAR 2 phase III study
    Bonomi, P
    Paz-Ares, L
    Langer, C
    O'Brien, M
    Gervais, R
    Gatzemeier, U
    Reiterer, R
    Orlov, S
    Ross, H
    Vandenbulcke, J
    [J]. LUNG CANCER, 2005, 49 : S35 - S35
  • [2] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    Paz-Ares, L.
    Ross, H.
    O'Brien, M.
    Riviere, A.
    Gatzemeier, U.
    Von Pawel, J.
    Kaukel, E.
    Freitag, L.
    Digel, W.
    Bischoff, H.
    Garcia-Campelo, R.
    Iannotti, N.
    Reiterer, P.
    Bover, I.
    Prendiville, J.
    Eisenfeld, A. J.
    Oldham, F. B.
    Bandstra, B.
    Singer, J. W.
    Bonomi, P.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 98 (10) : 1608 - 1613
  • [3] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    L Paz-Ares
    H Ross
    M O'Brien
    A Riviere
    U Gatzemeier
    J Von Pawel
    E Kaukel
    L Freitag
    W Digel
    H Bischoff
    R García-Campelo
    N Iannotti
    P Reiterer
    I Bover
    J Prendiville
    A J Eisenfeld
    F B Oldham
    B Bandstra
    J W Singer
    P Bonomi
    [J]. British Journal of Cancer, 2008, 98 : 1608 - 1613
  • [4] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [5] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    [J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [6] IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Chen, Gongyan
    He, Jianxing
    Feng, Jifeng
    Zhang, Yiping
    Jiang, Liyan
    Pan, Hongming
    Chang, Jianhua
    Fang, Jian
    Cai, Amy
    Bu, Lilian
    Shi, Jane
    Xia, Jinjing
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (02)
  • [7] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [8] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [9] Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment
    Ravasio, Roberto
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) : 119 - 126
  • [10] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
12345